Skip to main content

Table 3 Tumor response according to RECIST 1.1, PERCIST 1.0, and histopathology

From: Role of 18 fluorine-fluorodeoxyglucose positron emission tomography/computed tomography in assessment of neoadjuvant chemotherapy response in breast cancer patients

Response

No. of patients

RECIST 1.1

 Responders

20 (66.7%)

 Non-responders

10 (33.3%)

PERCIST 1.0

 Responders

23 (76.7%)

  CMR

5 (16.7%)

  PMR

18 (60%)

 Non-responders

7 (23.3%)

  SMD

4 (13.3)

  PMD

3 (10%)

Pathologic response

 Responders

22 (73.3%)

  Grade 3

14 (46.7%)

  Grade 4

4 (13.3%)

  Grade 5

4 (13.3%)

 Non-responders

8 (26.7%)

  Grade 1

1 (3.3%)

  Grade 2

7 (23.3%)